• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Medicine (Baltimore) . Anti-N-methyl-D-aspartate receptor encephalitis after coronavirus disease 2019: A case report and literature review

tetano

Editor, Senior Moderator
Medicine (Baltimore)


. 2022 Sep 2;101(35):e30464.
doi: 10.1097/MD.0000000000030464.
Anti-N-methyl-D-aspartate receptor encephalitis after coronavirus disease 2019: A case report and literature review


Hyesun Lee[SUP] 1 [/SUP], Jong Hyun Jeon, Hojin Choi, Seong-Ho Koh, Kyu-Yong Lee, Young Joo Lee, Hyuk Sung Kwon



Affiliations

Abstract

Rationale: Coronavirus disease 2019 (COVID-19) has become a global pandemic and COVID-19-associated anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis may occur through an immune-mediated pathomechanism.
Patient concerns: A 21-year-old woman with a history of COVID-19 presented to our hospital with memory decline and psychiatric symptoms.
Diagnosis: The patient was diagnosed with anti-NMDAR encephalitis.
Intervention: Intravenous methylprednisolone (1 g/day over 5 days) followed by immunoglobulin (0.4 g/kg/day over 5 days) were administered. The patient underwent laparoscopic salpingo-oophorectomy to remove an ovarian teratoma.
Outcomes: The patient was discharged with sequelae of short-term memory impairment, without other neuropsychiatric symptoms.
Lessons: Cases of previously reported anti-NMDAR encephalitis with COVID-19 were reviewed and compared with the present case. Clinicians should be aware of the occurrence of anti-NMDAR encephalitis in patients who present with neuropsychiatric complaints during or after exposure to COVID-19. Further studies are required to determine the causal relationship between the 2 diseases and predict the prognosis of anti-NMDAR encephalitis after COVID-19 exposure.
 
Back
Top Bottom